Galectin Therapeutics Inc. last reported quarterly results on Aug 14, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.14. It usually reports 45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 14, 2026
45 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-9
-21.2%
|
-0.14
-16.7%
|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-5
+47.6%
|
-0.08
+46.7%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-8
+27.1%
|
-0.13
+27.8%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-8
+39.2%
|
-0.12
+40.0%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-10
+16.2%
|
-0.15
+21.1%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-11
-7.6%
|
-0.18
+25.0%
|
|
Aug 13, 2024
44 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Norcross, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133416
- Former names
- PRO PHARMACEUTICALS INC (until May 26, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.